Galenica reported strong FY21 sales growth of 10.2%, driven by 13.4% growth in the Products & Care segment and a 7.9% rise in Logistics & IT segment revenue. The former benefited from 29.2% growth in the online & mail-order pharmacy channel (reported as Pharmacies-at-home) and a 17.8% uptick in Products & Brands revenue. Following the strong sales update, Galenica now expects FY21 EBIT growth of 24-28%. We expect to upgrade our FY21 numbers following the trading update.
21 Jan 2022
Strong FY 21 sales drives EBIT upgrade
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong FY 21 sales drives EBIT upgrade
Galenica reported strong FY21 sales growth of 10.2%, driven by 13.4% growth in the Products & Care segment and a 7.9% rise in Logistics & IT segment revenue. The former benefited from 29.2% growth in the online & mail-order pharmacy channel (reported as Pharmacies-at-home) and a 17.8% uptick in Products & Brands revenue. Following the strong sales update, Galenica now expects FY21 EBIT growth of 24-28%. We expect to upgrade our FY21 numbers following the trading update.